Championing A Cure For Muscular Dystrophy and other Genetic Diseases: Scott Rockledge

The life sciences have always been a passionate pursuit for Scott Rockledge. His expertise is in healthcare management. He has worked with Cubist Pharmaceuticals in testing effective treatments and drug trials for genetic disorders. He also worked in research and development at Salutar and Catalytica for a number of clinical trials. His accomplishments include the FDA approval of three new drug applications for Omniscan™, Teslascan®, and Cubicin®.


Rockledge’s experience in life science management, specifically in the pharmaceutical industry, led him to join 5AM Ventures in 2003. 5AM Ventures utilizes a hands-on approach when investing in entrepreneurs in the healthcare industry. This hands-on approach has recently provided much-needed support for Expansion Therapeutics. Expansion Therapeutics is looking to raise Series A financing for a potential treatment for muscular dystrophy and other genetic diseases. Learn more:


Matthew D. Disney, Ph.D. is heading the research to control the RNA molecules that can become toxic when it reaches a certain level. Myotonic dystrophy type 1 (DM1) is the type of muscular dystrophy found in adults. The research that Dr. Disney and his colleagues at Expansion Therapeutics looks promising. Small molecule medications are proven to be effective in some cases. Dr. Disney is hopeful that in time many of these disease-related RNA issues can be addressed.


Rockledge has formulated a plan based on Disney’s research on the effects of RNA on cells. This knowledge will help advance the field of research into the cures for these devasting diseases.


Rockledge’s team of life science experts provide a wealth of information and resources to support entrepreneurs who are working to cure genetic diseases. Rockledge’s mission is to help scientists, researchers and other interested parties reach their goals. It is important to him that they get the support they need to help patients with unmet needs. Rockledge is happy to support Expansion Therapeutics’ endeavors to find a cure for muscular dystrophy.


The strategy that Rockledge adheres to in his everyday life shows in his organizational skills and his eagerness to embrace new technologies. He advises everyone that they shouldn’t be afraid of measured risk-taking. He supports healthcare entrepreneurs wholeheartedly